H.C. Wainwright lowered the firm’s price target on Applied DNA Sciences to $1.50 from $2 and keeps a Buy rating on the shares. The company’s revenue exhibited sequential growth in fiscal Q1, the analyst tells investors in a research note. The firm believes Applied’s revenue may increase significantly in the second half of 2024, driven by customer orders for critical starting materials for mRNA therapeutics.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on APDN: